Incidence and Predictors of Hypoglycaemia in Type 2 Diabetes - an Analysis of the Prospective DiaRegis Registry

Overview

Journal BMC Endocr Disord

Publisher Biomed Central

Specialty Endocrinology

Date 2012 Oct 19

PMID 23075070

Citations 24

Authors

Diethelm Tschope

Peter Bramlage

Christiane Binz

Michael Krekler

Evelin Deeg

Anselm K Gitt

Affiliations

Soon will be listed here.

Abstract

Unlabelled:

Background: Hypoglycaemia is a serious adverse effect of antidiabetic drug therapy. We aimed to determine incidence rates of hypoglycaemia in type-2 diabetic patients and identify predictors of hypoglycaemia when treatment is intensified.

Methods: DiaRegis is a prospective German registry that follows 3810 patients with type-2 diabetes referred for treatment intensification because of insufficient glycaemic control on one or two oral antidiabetic drugs.

Results: Out of a total of 3347 patients with data available for the present analysis 473 (14.1%) presented any severity hypoglycaemia over a follow-up of 12 months. 0.4% were hospitalized (mean of 1.3±0.6 episodes), 0.1% needed medical assistance (1.0±0.0), 0.8% needed any help (1.1±0.5) and 10.1% no help (3.4±3.7), and 8.0% had no specific symptoms (3.6±3.5). Patients with incident hypoglycaemia had longer diabetes duration, higher HbA1c and a more frequent smoking history; more had co-morbid disease conditions such as coronary artery disease, peripheral arterial disease, amputation, heart failure, peripheral neuropathy, diabetic retinopathy and clinically relevant depression at baseline. Multivariable adjusted positive predictors of incident hypoglycaemia over the follow-up were prior anamnestic hypoglycaemia, retinopathy, depression, insulin use and blood glucose self-measurement, but not sulfonylurea use as previously reported for anamnestic or recalled hypogylcaemia. On the contrary, glitazones, DPP-4 inhibitors and GLP-1 analogues were associated with a reduced risk of hypoglycaemia.

Conclusions: Hypoglycaemia is a frequent adverse effect in ambulatory patients when antidiabetic treatment is intensified. Particular attention is warranted in patients with prior episodes of hypoglycaemia, microvascular disease such as retinopathy and in patients receiving insulin. On the other hand glitazones, DPP-4 inhibitors and GLP-1 analogues are associated with a reduced risk.

Citing Articles

Insulin therapy among diabetic patients in rural communities of Sub-Saharan Africa: a perspective review.

Kiconco R, Lumumba S, Nkubi Bagenda C, Atwine R, Ndarubweine J, Rugera S Ther Adv Endocrinol Metab. 2024; 15:20420188241232280.

PMID: 38379780 PMC: 10878220. DOI: 10.1177/20420188241232280.

Vonna A, Salahudeen M, Peterson G J Clin Med. 2024; 13(2).

PMID: 38256662 PMC: 10817070. DOI: 10.3390/jcm13020530.

Effects of Hypoglycemia on Cardiovascular Function in Patients with Diabetes.

Christou M, Christou P, Kyriakopoulos C, Christou G, Tigas S Int J Mol Sci. 2023; 24(11).

PMID: 37298308 PMC: 10253702. DOI: 10.3390/ijms24119357.

Hypoglycemic Risk Factors Among Hospitalized Patients with Type 2 Diabetes Mellitus at King Abdulaziz Medical City, Jeddah.

Alghamdi E, Alghubayshi L, Alshamrani R, Alnajashi R, Alamoudi E, Aljabarti A Cureus. 2020; 12(1):e6742.

PMID: 32133264 PMC: 7034734. DOI: 10.7759/cureus.6742.

Smoking in men and women with type 2 diabetes: A qualitative gender-sensitive exploration of barriers to smoking cessation among people with type 2 diabetes.

Georges A, Galbiati L, Clair C PLoS One. 2019; 14(8):e0221783.

PMID: 31461485 PMC: 6713328. DOI: 10.1371/journal.pone.0221783.

References

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Henderson J, Allen K, Deary I, Frier B . Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med. 2003; 20(12):1016-21. DOI: 10.1046/j.1464-5491.2003.01072.x. View

Russell-Jones D, Vaag A, Schmitz O, Sethi B, Lalic N, Antic S . Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009; 52(10):2046-55. PMC: 2744824. DOI: 10.1007/s00125-009-1472-y. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Bott S, Bott U, Berger M, Muhlhauser I . Intensified insulin therapy and the risk of severe hypoglycaemia. Diabetologia. 1997; 40(8):926-32. DOI: 10.1007/s001250050769. View

Bramlage P, Gitt A, Binz C, Krekler M, Deeg E, Tschope D . Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol. 2012; 11:122. PMC: 3508810. DOI: 10.1186/1475-2840-11-122. View

Choudhary P, Amiel S . Hypoglycaemia: current management and controversies. Postgrad Med J. 2011; 87(1026):298-306. DOI: 10.1136/pgmj.2008.068197. View

Boucai L, Southern W, Zonszein J . Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities. Am J Med. 2011; 124(11):1028-35. PMC: 3200530. DOI: 10.1016/j.amjmed.2011.07.011. View

. UK prospective study of therapies of maturity-onset diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Diabetologia. 1983; 24(6):404-11. View

10.

Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24):2560-72. DOI: 10.1056/NEJMoa0802987. View

11.

Jones T, Porter P, Sherwin R, Davis E, OLeary P, Frazer F . Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med. 1998; 338(23):1657-62. DOI: 10.1056/NEJM199806043382303. View

12.

Donnelly L, Morris A, Frier B, Ellis J, Donnan P, Durrant R . Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med. 2005; 22(6):749-55. DOI: 10.1111/j.1464-5491.2005.01501.x. View

13.

Amiel S, Maran A, Powrie J, Umpleby A, MacDonald I . Gender differences in counterregulation to hypoglycaemia. Diabetologia. 1993; 36(5):460-4. DOI: 10.1007/BF00402284. View

14.

Kendall D, Riddle M, Rosenstock J, Zhuang D, Kim D, Fineman M . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28(5):1083-91. DOI: 10.2337/diacare.28.5.1083. View

15.

Williams S, Pollack M, DiBonaventura M . Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2011; 91(3):363-70. DOI: 10.1016/j.diabres.2010.12.027. View

16.

Davis S, Shavers C, Costa F . Gender-related differences in counterregulatory responses to antecedent hypoglycemia in normal humans. J Clin Endocrinol Metab. 2000; 85(6):2148-57. DOI: 10.1210/jcem.85.6.6641. View

17.

Zoungas S, Patel A, Chalmers J, de Galan B, Li Q, Billot L . Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010; 363(15):1410-8. DOI: 10.1056/NEJMoa1003795. View

18.

Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Johnsen K, Thorsteinsson B . Prospective and retrospective recording of severe hypoglycaemia, and assessment of hypoglycaemia awareness in insulin-treated Type 2 diabetes. Diabet Med. 2009; 26(12):1306-8. DOI: 10.1111/j.1464-5491.2009.02834.x. View

19.

Foley J, Sreenan S . Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. Horm Metab Res. 2009; 41(12):905-9. DOI: 10.1055/s-0029-1234042. View

20.

Holstein A, Plaschke A, Egberts E . Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2002; 17(6):467-73. DOI: 10.1002/dmrr.235. View